First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children’s Oncology Group Phase 1/Pilot Consortium

PURPOSE: Characterize the pharmacokinetics of oral crizotinib in children with cancer. METHODS: Sixty-four children with solid tumors or anaplastic large-cell lymphoma (ALCL) enrolled on a phase 1/2 trial of the ALK, MET and ROS1 inhibitor, crizotinib, had pharmacokinetic sampling after the first do...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Chemother Pharmacol
Autori principali: Balis, Frank M., Thompson, Patrick A., Mosse, Yael P., Blaney, Susan M., Minard, Charles G., Weigel, Brenda J., Fox, Elizabeth
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer Berlin Heidelberg 2016
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5225209/
https://ncbi.nlm.nih.gov/pubmed/28032129
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-016-3220-6
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi